STAT+: Pharmalittle: Glaxo and Sanofi start new trial of Covid-19 vaccine; AstraZeneca ends a drug’s use for bladder cancer after failed trial

Good morning, everyone, and welcome to another working week. We hope the weekend respite was somehow relaxing and invigorating, because that oh-so predictable routine of Zoom meetings, Skype calls, and deadlines has returned. After all, the world keeps spinning. So why not give it a little push with a cup of stimulation in hand? Our choice today is vanilla caramel cream. Feel free to join us. Meanwhile, here are a few items of interest to help you on your own journey. We hope all goes well today and, of course, do stay in touch. …

GlaxoSmithKline (GSK) and Sanofi (SNY) have started a new clinical trial of their protein-based Covid-19 vaccine candidate, reviving their efforts against the pandemic after a setback in December delayed the shot’s launch, Reuters writes. The drug makers aim to reach final testing in the second quarter, and if results are conclusive, hope to win approval by the fourth quarter after having initially targeted the first half of this year. In December 2020, the companies disclosed clinical trials showed an insufficient immune response in older people.

Continue to STAT+ to read the full story…